Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas

NCT03233724 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

9

Enrollment

NIH

Sponsor class

Stopped Study terminated due to drug supply issues.

Conditions

Carcinoma, Non-Small-Cell Lung
Lung Cancer
Non-Small Cell Lung Cancer
Carcinoma, Esophageal
Malignant Pleural Mesotheliomas

Interventions

DRUG: Decitabine (DAC)
DRUG: Tetrahydrouridine (THU)
DRUG: Pembrolizumab

Sponsor

National Cancer Institute (NCI)